Baillie Gifford & CO Bei Gene, Ltd. Transaction History

Baillie Gifford & CO

$126 Billion
Q1 2024

A detailed history of Baillie Gifford & CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Baillie Gifford & CO holds 3,728,730 shares of BGNE stock, worth $555 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares

3,728,730

Previous 3,866,449 3.56%

Holding current value

$555 Million

Previous $697 Million 16.38%

% of portfolio

0.46%

Previous 0.56%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$141.8 - $181.47 $19.5 Million - $25 Million	-137,719 Reduced 3.56%	3,728,730 $583 Million
Q4 2023 Jan 26, 2024	SELL	$158.67 - $201.58 $816,991 - $1.04 Million	-5,149 Reduced 0.13%	3,866,449 $697 Million
Q3 2023 Nov 13, 2023	BUY	$179.87 - $225.13 $106 Million - $132 Million	588,294 Added 17.92%	3,871,598 $696 Million
Q2 2023 Jul 28, 2023	SELL	$178.3 - $266.78 $6.07 Million - $9.09 Million	-34,058 Reduced 1.03%	3,283,304 $585 Million
Q1 2023 May 03, 2023	SELL	$215.53 - $274.5 $19.7 Million - $25.1 Million	-91,357 Reduced 2.68%	3,317,362 $715 Million

Q4 2022 Jan 24, 2023	BUY	$125.51 - $229.3 $24.9 Million - $45.6 Million	198,778 Added 6.19%	3,408,719 $750 Million
Q3 2022 Oct 27, 2022	SELL	$131.8 - $202.24 $3.29 Million - $5.05 Million	-24,990 Reduced 0.77%	3,209,941 $433 Million
Q2 2022 Aug 08, 2022	SELL	$121.11 - $216.05 $105 Million - $188 Million	-868,037 Reduced 21.16%	3,234,931 $524 Million
Q1 2022 May 05, 2022	SELL	$146.52 - $269.56 $3.07 Million - $5.64 Million	-20,931 Reduced 0.51%	4,102,968 $774 Million
Q4 2021 Jan 20, 2022	SELL	$248.56 - $389.34 $31.1 Million - $48.7 Million	-125,153 Reduced 2.95%	4,123,899 $1.12 Billion
Q3 2021 Oct 19, 2021	SELL	$249.6 - $403.14 $5.77 Million - $9.32 Million	-23,126 Reduced 0.54%	4,249,052 $1.54 Billion
Q2 2021 Aug 02, 2021	SELL	$292.75 - $367.01 $45.8 Million - $57.5 Million	-156,537 Reduced 3.53%	4,272,178 $1.47 Billion
Q1 2021 May 06, 2021	BUY	$260.64 - $382.12 $47.1 Million - $69.1 Million	180,888 Added 4.26%	4,428,715 $1.54 Billion
Q4 2020 Feb 10, 2021	BUY	$221.31 - $316.61 $622 Million - $891 Million	2,812,638 Added 195.98%	4,247,827 $1.1 Billion
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $210 Million - $318 Million	1,109,006 Added 340.0%	1,435,189 $411 Million
Q2 2020 Aug 12, 2020	BUY	$123.9 - $195.41 $2.99 Million - $4.72 Million	24,160 Added 8.0%	326,183 $61.5 Million
Q1 2020 May 08, 2020	BUY	$121.84 - $173.19 $1.63 Million - $2.31 Million	13,348 Added 4.62%	302,023 $37.2 Million
Q4 2019 Feb 10, 2020	SELL	$115.78 - $208.34 $23.2 Million - $41.7 Million	-200,219 Reduced 40.95%	288,675 $47.9 Million
Q3 2019 Nov 07, 2019	BUY	$120.61 - $148.29 $47.1 Million - $57.9 Million	390,370 Added 396.22%	488,894 $59.9 Million
Q2 2019 Aug 08, 2019	BUY	$113.99 - $146.86 $336,270 - $433,237	2,950 Added 3.09%	98,524 $12.2 Million
Q1 2019 May 01, 2019	BUY	$122.82 - $151.83 $105,379 - $130,270	858 Added 0.91%	95,574 $0
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $1.38 Million - $2.27 Million	12,938 Added 15.82%	94,716 $13.3 Million
Q3 2018 Nov 13, 2018	SELL	$152.62 - $189.66 $250,449 - $311,232	-1,641 Reduced 1.97%	81,778 $14.1 Million
Q2 2018 Jul 17, 2018	SELL	$152.5 - $216.77 $609,695 - $866,646	-3,998 Reduced 4.57%	83,419 $12.8 Million
Q1 2018 May 10, 2018	BUY	$97.41 - $177.22 $16,170 - $29,418	166 Added 0.19%	87,417 $14.7 Million
Q4 2017 Feb 13, 2018	BUY	$79.6 - $114.73 $576,383 - $830,759	7,241 Added 9.05%	87,251 $8.53 Million
Q3 2017 Oct 20, 2017	BUY	$66.19 - $103.46 $369,737 - $577,927	5,586 Added 7.51%	80,010 $8.28 Million
Q2 2017 Aug 10, 2017	BUY	N/A	74,424	74,424 $3.35 Million

Others Institutions Holding BGNE

# of Institutions

216

Shares Held

45.1M

Call Options Held

76.5K

Put Options Held

72.3K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $15.4B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Bei Gene, Ltd. Transaction History